Volume 17, Issue 1 (Winter 2026)
Caspian J Intern Med 2026, 17(1): 90-96 |
Back to browse issues page
Seyedeh Niloufar Mousavi 
, Aida Khademolhosseini , Mohammad Javad Fattahi , Soolmaz Khansalar , Sedigheh Tahmasebi , Abbas Ghaderi , Mohammad Reza Haghshenas *
, Aida Khademolhosseini , Mohammad Javad Fattahi , Soolmaz Khansalar , Sedigheh Tahmasebi , Abbas Ghaderi , Mohammad Reza Haghshenas *
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran , haghshenasmr@sums.ac.ir
Abstract: (1257 Views)
Background: Interleukin-38 (IL-38) is an anti-inflammatory cytokine with immunomodulatory properties, but its role in breast cancer (BC) is unclear. This study aimed to evaluate IL-38 serum levels in BC patients aged ≤40 and ≥50 years and to correlate the findings with clinicopathological features.
Methods: IL-38 levels were measured using an enzyme-linked immunosorbent assay (ELISA) in the serum of 30 BC patients aged ≤40, 30 aged ≥50, and 30 healthy controls. Non-parametric tests were used for statistical comparisons, and Spearman's correlation was used to examine the correlation between IL-38 and age and tumor size.
Results: There was no significant difference in serum IL-38 levels between patients aged ≥50 and those aged ≤40 or their age-matched controls. However, patients aged ≤40 years had significantly lower IL-38 levels than healthy individuals of the same age (P=0.003). In addition, serum IL-38 levels were significantly different between healthy individuals aged ≤40 and ≥50 years. Patients with stage I and II BC had significantly lower serum IL-38 levels than healthy controls (P=0.04 and P=0.003, respectively). However, there were no significant associations between IL-38 serum levels and histological grade (P=0.09), nuclear grade (P=0.11), lymphovascular invasion (P=0.72), perineural invasion (P=0.21), lymph node involvement (P=0.71) and tumor size (P=0.70).
Conclusion: Our results suggest that any change in IL-38 serum levels is likely to affect the anti-inflammatory response in BC patients, especially those under 40 years of age. However, this is a preliminary study, and further studies with larger cohorts are needed to validate these findings.
Methods: IL-38 levels were measured using an enzyme-linked immunosorbent assay (ELISA) in the serum of 30 BC patients aged ≤40, 30 aged ≥50, and 30 healthy controls. Non-parametric tests were used for statistical comparisons, and Spearman's correlation was used to examine the correlation between IL-38 and age and tumor size.
Results: There was no significant difference in serum IL-38 levels between patients aged ≥50 and those aged ≤40 or their age-matched controls. However, patients aged ≤40 years had significantly lower IL-38 levels than healthy individuals of the same age (P=0.003). In addition, serum IL-38 levels were significantly different between healthy individuals aged ≤40 and ≥50 years. Patients with stage I and II BC had significantly lower serum IL-38 levels than healthy controls (P=0.04 and P=0.003, respectively). However, there were no significant associations between IL-38 serum levels and histological grade (P=0.09), nuclear grade (P=0.11), lymphovascular invasion (P=0.72), perineural invasion (P=0.21), lymph node involvement (P=0.71) and tumor size (P=0.70).
Conclusion: Our results suggest that any change in IL-38 serum levels is likely to affect the anti-inflammatory response in BC patients, especially those under 40 years of age. However, this is a preliminary study, and further studies with larger cohorts are needed to validate these findings.
Policy Brief: Original Article |
Subject:
Imonology
Received: 2024/12/24 | Accepted: 2025/04/6 | Published: 2026/01/21
Received: 2024/12/24 | Accepted: 2025/04/6 | Published: 2026/01/21
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |